F2RL1 and infection: To evaluate the potential of intranasal PAR2 antagonist treatment to reduce pathologic inflammation in the lung after IAV infection, WT mice were treated with an inhibitory PAR2 antibody (SAM11) or control IgG2a prior and during infection with IAV.